The first patient has been dosed in the DESTINY-Lung06 phase 3 trial evaluating ENHERTU (trastuzumab deruxtecan) plus pembrolizumab versus pembrolizumab, platinum-based chemotherapy and pemetrexed as a first-line treatment in patients with unresectable, locally advanced or metastatic HER2 overexpressing and PD-L1 TPS <50% non-squamous non-small cell lung cancer (NSCLC).
Health Technology Insights: Carenet Health Announces Christopher Rogers to Succeed Mick Mazour as President
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
One of the current recommended first-line treatments for patients with HER2 overexpressing metastatic non-squamous NSCLC is pembrolizumab plus platinum-based chemotherapy and pemetrexed. Improved outcomes for immunotherapy-based treatments correlate with higher PD-L1 levels, underscoring the need for more targeted treatment options for patients with PD-L1 TPS <50%.4 There currently are no HER2 directed medicines approved in the first-line setting of metastatic NSCLC.
Health Technology Insights: Ferring Highlights New Real-World Research with ADSTILADRIN in Clinical Practice
“DESTINY-Lung06 is evaluating a targeted treatment strategy for patients with HER2 overexpressing metastatic non-squamous non-small cell lung cancer with low PD-L1 expression,” said Abderrahmane Laadem, MD, Head, Late-Stage Oncology Clinical Development, Daiichi Sankyo. “In the trial, we are evaluating whether replacing traditional chemotherapy with ENHERTU and combining it with standard of care immunotherapy could potentially improve outcomes for patients in the first-line metastatic setting.”
Health Technology Insights: Altera Digital Health Launches CareInTelligence, a Data Platform for Payers
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
